Guía detallada disponible en inglés. MFMD ofrece orientación y coordinación del centro en español.
A new peptide should enter the practice through a defined service-line review — not because a vendor added it to a catalog or patients started asking for it. Before it reaches the menu, the clinic should confirm the specific product and the clinical, prescribing, pharmacy, evaluation, documentation, and monitoring structure around it.
Abrir la explicación completa2 secciones y fuentes primarias
What belongs on the review checklist before adding a peptide?
Exact substance and formulation; intended clinical use; available evidence; who will prescribe; pharmacy/source; route; patient-evaluation pathway; documentation; monitoring; adverse-event escalation; current pharmacy/compounding considerations; staff responsibilities; and patient communication.
Owner takeaway
Patient demand can start the conversation. It should not finish the governance review. This is where MFMD’s service-line development fits — see Add a Service Line.